EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Stability of Protein Pharmaceuticals: Recent Advances

Mark Cornell Manning, Ryan E Holcomb, Robert W Payne, Joshua M Stillahn, Brian D Connolly, Derrick S Katayama, Hongcheng Liu, James E Matsuura, Brian M Murphy, Charles S Henry, Daan J A Crommelin

Pharmaceutical Research · 2024-07 · 41 (7) · 1301-1367

DOI: 10.1007/s11095-024-03726-x ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Pharmaceutical Research, online erschienen am 27.06.2024. Verfasst von Mark Cornell Manning und 10 weiteren Autor:innen. Beteiligte Einrichtung: Legacy BioDesign LLC, Johnstown, CO, USA. manning@legacybiodesign.com. Hauptthemen laut MEDLINE: Protein Stability, Proteins, Drug Stability. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 1174 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There have been significant advances in the formulation and stabilization of proteins in the liquid state over the past years since our previous review. Our mechanistic understanding of protein-excipient interactions has increased, allowing one to develop formulations in a more rational fashion. The field has moved towards more complex and challenging formulations, such as high concentration formulations to allow for subcutaneous administration and co-formulation. While much of the published work has focused on mAbs, the principles appear to apply to any therapeutic protein, although mAbs clearly have some distinctive features. In this review, we first discuss chemical degradation reactions. This is followed by a section on physical instability issues. Then, more specific topics are addressed: instability induced by interactions with interfaces, predictive methods for physical stability and interplay between chemical and physical instability. The final parts are devoted to discussions how all the above impacts (co-)formulation strategies, in particular for high protein concentration solutions.'

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein StabilityProteinsDrug StabilityHumansExcipientsDrug CompoundingChemistry, PharmaceuticalAnimalsAntibodies, Monoclonal

Stichwörter der Autor:innen

co-formulationformulationmonoclonal antibodiesprotein stabilityproteins

Substanzen

ProteinsExcipientsAntibodies, Monoclonal

Autor:innen und Institutionen

  • Legacy BioDesign LLC, Johnstown, CO, USA. manning@legacybiodesign.com.
  • Department of Chemistry, Colorado State University, Fort Collins, CO, USA. manning@legacybiodesign.com.
  • Legacy BioDesign LLC, Johnstown, CO, USA.
  • Department of Chemistry, Colorado State University, Fort Collins, CO, USA.
  • Spyre Therapeutics, Inc., Waltham, MA, USA.
  • Samsung Biologics, 201-2, Songdo-Dong, Yeonsu-Gu, Incheon, Korea.

Zitieren

APA

Manning, M. C., Holcomb, R. E., Payne, R. W., Stillahn, J. M., Connolly, B. D., Katayama, D. S., Liu, H., Matsuura, J. E., Murphy, B. M., Henry, C. S., & Crommelin, D. J. A. (2024). Stability of Protein Pharmaceuticals: Recent Advances. Pharmaceutical Research, 41(7), 1301-1367. https://doi.org/10.1007/s11095-024-03726-x

Vancouver

Manning MC, Holcomb RE, Payne RW, Stillahn JM, Connolly BD, Katayama DS, et al. Stability of Protein Pharmaceuticals: Recent Advances. Pharmaceutical Research. 2024;41(7):1301-1367. doi:10.1007/s11095-024-03726-x

BibTeX
@article{Manning2024,
  author = {Manning, Mark Cornell and Holcomb, Ryan E and Payne, Robert W and Stillahn, Joshua M and Connolly, Brian D and Katayama, Derrick S and Liu, Hongcheng and Matsuura, James E and Murphy, Brian M and Henry, Charles S and Crommelin, Daan J A},
  title = {Stability of Protein Pharmaceuticals: Recent Advances},
  journal = {Pharmaceutical Research},
  year = {2024},
  volume = {41},
  number = {7},
  pages = {1301--1367},
  doi = {10.1007/s11095-024-03726-x}
}
Kostenlos starten →